Background Deletions and point mutations of the p16 gene are detectable in more than 50%
of ovarian cancer cells. In this study, we examined the effect of p16 gene transduction on the …

Cyclin-dependent kinase inhibitors are potent suppressors of cell growth and have been
proposed as targets for gene replacement therapy in cancer. Expression of either p16INK4a …

Clinical adenoviral p53 gene therapy has been shown by us and others to inhibit tumor
growth of ovarian cancer with endogenous mutant p53. This study was designed to test the …

Clonogenic survival and early cell death during treatment of human colon carcinoma cells
were investigated following X‐irradiation (IR) alone, IR followed by 5‐FU for 24 h, and Taxol …

7-hydroxystaurosporine (UCN-01) is a more selective protein kinase C inhibitor than
staurosporine. UCN-01 exhibits antitumor activity in experimental tumor models and is …

Recent evidence has suggested that tumor cells having a wild-type p53 status are more
sensitive to chemotherapeutic agents and radiation than cells that lack functional p53. The …

Mutations in the tumor suppressor gene TP5 3 represent the most frequent genetic
difference between tumor cells and normal cells. Here, we have attempted to turn this …

Activation of the tumor suppressor protein p53 can lead to arrest in both G1 and G2 stages of
the cell cycle and, in some cells, to apoptotic cell death. In this study, we showed that the …

CHS 828, a novel cyanoguanidine, represents a new class of drugs for cancer therapy, with
an unknown primary mechanism of action. It is generally known that anticancer drugs induce …

Purpose: We evaluated apoptotic, necrotic and clonogenic cell death and inhibition of cell
growth in a human melanoma cell line (Sk-Mel-3) and a normal human fibroblast cell line …